NDA 216196 · Agios Pharms INC
Pyrukynd
Mitapivat Sulfate · Oral · Pyruvate Kinase Activator
NovelPriority reviewOrphanCDER novel approval, Feb 17, 2022: To treat hemolytic anemia in pyruvate kinase deficiency
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Feb 17, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
29
11 Phase 3, 3 recruiting
FAERS reports
1,331
199 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOCELLULAR INJURY AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase, and total bilirubin with fractionation) at baseline and every 4 weeks for 24 weeks and then as clinically indicated. Avoid use of AQVESME in patients with cirrhosis. Discontinue AQVESME if hepatic injury is suspected [see Warnings and Precautions ( 5.1 )] . Because of the risk of hepatocellular injury, AQVESME is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AQVESME REMS [see Warnings and Precautions ( 5.2 )] . WARNING: HEPATOCELLULAR INJURY See full prescribing information for complete boxed warning. AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase, and total bilirubin with fractionation) at baseline and every 4 weeks...
What it is approved for
From the label in effect Aug 27, 2026.
AQVESME is indicated for the treatment of anemia in adults with alpha- or beta-thalassemia. AQVESME is a pyruvate kinase activator indicated for the treatment of anemia in adults with alpha- or beta-thalassemia. ( 1.1 )
Mechanism: Mitapivat is a pyruvate kinase activator that acts by allosterically binding to the pyruvate kinase tetramer and increasing pyruvate kinase (PK) activity. Imbalances in globin chain production during erythropoiesis result in increased oxidative stress, which leads to ineffective erythropoiesis and hemolysis. In nonclinical models of beta-thalassemia, mitapivat improved energy homeostasis, RBC longevity, ineffective erythropoiesis, and hemolysis by increasing PK activity.
Therapeutic areas: Hematology and blood cancers · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 2025 Supplement 3 · Efficacy OrphanLabelMedication GuideLetter
- Feb 17, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
4 products under this application
- PYRUKYND · MITAPIVAT SULFATE EQ 20MG BASE · TABLET, ORAL · Prescription
- PYRUKYND · MITAPIVAT SULFATE EQ 50MG BASE · TABLET, ORAL · Prescription
- PYRUKYND · MITAPIVAT SULFATE EQ 5MG BASE · TABLET, ORAL · Prescription
- AQVESME · MITAPIVAT SULFATE EQ 100MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mitapivat" as an intervention, any sponsor and status, largest first.
- A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)Pivotal-lookingActive, not recruiting
Agios Pharmaceuticals, Inc.Industry
NCT05031780 · 286 participants · Start Feb 11, 2022 · Primary completion Oct 30, 2025
Drug: Mitapivat · For: Sickle Cell Disease
Sites: La Jolla, California; Los Angeles, California; Oakland, California · 91 sites in all
- A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Pivotal-lookingActive, not recruiting
Agios Pharmaceuticals, Inc.Industry
NCT04770779 · 258 participants · Start Nov 30, 2021 · Primary completion Apr 11, 2024
Drug: Placebo Matching Mitapivat; Mitapivat · For: Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia
Sites: Phoenix, Arizona; La Jolla, California; Oakland, California · 75 sites in all
- A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Pivotal-lookingActive, not recruiting
Agios Pharmaceuticals, Inc.Industry
NCT04770753 · 194 participants · Start Dec 20, 2021 · Primary completion Nov 13, 2023
Drug: Placebo Matching Mitapivat; Mitapivat · For: Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia
Sites: La Jolla, California; Palo Alto, California; Boston, Massachusetts · 68 sites in all
- A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)Pivotal-lookingRecruiting
Agios Pharmaceuticals, Inc.Industry
NCT07656415 · 159 participants (planned) · Start Jul 21, 2026 · Primary completion Aug 2029
Drug: Mitapivat Matched Placebo; Mitapivat · For: Sickle Cell Disease
Sites: Indianapolis, Indiana; Grand Rapids, Michigan; Flowood, Mississippi · 5 sites in all
- Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007Pivotal-lookingCompleted
Agios Pharmaceuticals, Inc.Industry
NCT03853798 · 90 participants · Start Mar 21, 2019 · Primary completion Jul 3, 2024
Drug: Mitapivat · For: Pyruvate Kinase Deficiency
Sites: Phoenix, Arizona; Oakland, California; Atlanta, Georgia · 42 sites in all
- A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)Pivotal-lookingCompleted
Agios Pharmaceuticals, Inc.Industry
NCT03548220 · 80 participants · Start Aug 9, 2018 · Primary completion Oct 9, 2020
Drug: Placebo; AG-348 · For: Pyruvate Kinase Deficiency; Anemia, Hemolytic
Sites: Little Rock, Arkansas; Atlanta, Georgia; Indianapolis, Indiana · 46 sites in all
Agios Pharmaceuticals, Inc.Industry
NCT03250598 · 60 participants · Start Aug 9, 2017 · Primary completion Oct 2, 2017
Drug: AG-348; AG-348 and 1 more · For: Healthy; Japanese; Non-Asian
Sites: Cypress, California
- A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyEnrolling by invitation
Agios Pharmaceuticals, Inc.Industry
NCT05777993 · 55 participants (planned) · Start Jul 6, 2023 · Primary completion Aug 2029
Drug: Mitapivat · For: Pyruvate Kinase Deficiency; Anemia, Hemolytic; Sickle Cell Disease and 1 more
Sites: Anderlecht, Belgium; Porto Alegre, Brazil; Campinas, Brazil · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemoglobin decreased230
- product dose omission issue197
- headache173
- fatigue159
- insomnia124
- off label use123
- nausea86
- arthralgia82
- drug ineffective76
- back pain64
- dizziness56
- asthenia52
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 119 |
| 2023 | 182 |
| 2024 | 192 |
| 2025 | 217 |
| 2026 | 621 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pyrukynd (Mitapivat Sulfate)
2024 spending
$6.0M
Beneficiaries
26
226 claims
Per beneficiary
$230,488
$467.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,573,075 |
| 2023 | $4,466,375 |
| 2024 | $5,992,677 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H, Galactéros F, Glenthøj A, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ, Al-Samkari H, Grace RF, et al. · Blood Adv 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
Idowu M, Otieno L, Dumitriu B, et al. · Lancet Haematol 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J, Horenstein M, Kim A, et al. · Am J Ther 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease.
D'Alessandro A, Le K, Lundt M, et al. · Haematologica 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
Taher AT, Al-Samkari H, Aydinok Y, et al. · Lancet 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Agios Pharms INC · Also marketed as Aqvesme
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.